Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06329544 · ClinicalTrials.gov registry record · NA

High Fructose Diet, the Gut Microbiome, and Metabolic Health

A NA study of Obesity and Type 2 Diabetes, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06329544: Recruiting NA study of Obesity and Type 2 Diabetes, sponsored by Icahn School of Medicine at Mount Sinai.

NCT06329544 is a NA study of Obesity and Type 2 Diabetes that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 30 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06329544, a NA study of Obesity and Type 2 Diabetes, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary fructose and metabolic health are poorly understood. Malabsorption or incomplete metabolism of fructose in the small intestine is common in the population. Excess fructose reaches the colon where it may change the structure and function of the gut microbiome, alter bacterial metabolites and trigger inflammatory responses impacting T2D risk. To elucidate whether commonly consumed levels of dietary fructose influence metabolic outcomes through altering the gut microbiome, the research team will randomize 30 participants to a controlled cross-over dietary intervention, in which the participants will consume 12-day isocaloric, added fructose or glucose diets (25% of total calories) separated by a 10-day controlled diet washout period. The research team aims to: 1. Determine the relationships between high fructose consumption, the gut microbiome and metabolic risk. 2. Characterize the causal role(s) that fructose-induced alterations to the gut microbiome have on metabolic risk using a germ-free mouse model. The research team will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via MRI elastography. The research team will use novel statistical approaches, including Distributed Lag Modeling, to understand the complex relationships between diet, the microbiome, metabolites and health outcomes. The research team will then conduct controlled dietary interventions and fecal microbiome transplantation studies in germ-free mice. Donor fecal samples from human

Primary Outcome

Liver proton density fat fraction (PDFF) in %

Interventions

  • DIETARY_SUPPLEMENT Fructose
  • DIETARY_SUPPLEMENT glucose

Study Locations (1)

New York

  • Mount Sinai Morningside - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-10-08
Est. Completion 2028-08-31
Phase NA

What NCT06329544 shows while recruiting

NCT06329544 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (96% lower).

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Fructose is the first listed.

NCT06329544 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06329544 about?

NCT06329544 is a clinical study titled "High Fructose Diet, the Gut Microbiome, and Metabolic Health". Americans commonly consume excess amounts of dietary fructose. Added fructose has been shown to have an adverse impact on metabolic health, including increased insulin resistance and type 2 diabetes (T2D) risk. However, the mechanisms that link dietary fructose and metabolic health are poorly unders...

What is the current status of trial NCT06329544?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-10-08. Estimated completion is 2028-08-31.

What conditions does trial NCT06329544 study?

This clinical trial studies the following conditions: Obesity, Type 2 Diabetes, MASLD.

What interventions are being tested in trial NCT06329544?

The interventions under investigation include: Fructose (DIETARY_SUPPLEMENT), glucose (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06329544?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06329544 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06329544's enrollment target sits among peer trials

30 851st of 1053 higher than 173 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06329544, the US trial registry maintained by the National Library of Medicine. NCT06329544 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.